Covestor’s Summit Therapeutics SMMT Stock Holding History

Covestor’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6K	Buy	415 +55	+15%	+$975	﹤0.01%	1848
2026 Q1	$7K	Sell	360 -298	-45%	-$4.82K	﹤0.01%	1688
2025 Q4	$12K	Hold	658	–	–	0.01%	1498
2025 Q3	$14K	Buy	658 +2	+0.3%	+$49	0.01%	1439
2025 Q2	$14K	Sell	656 -2	-0.3%	-$46	0.01%	1387
2025 Q1	$13K	Buy	658 +3	+0.5%	+$60	0.01%	1366
2024 Q4	$12K	Sell	655 -578	-47%	-$11.2K	0.01%	1443
2024 Q3	$27K	Buy	1,233 +1,190	+2,767%	+$16.6K	0.02%	1112
2024 Q2	$0	Hold	43	–	–	﹤0.01%	2708
2024 Q1	$0	Sell	43 -21	-33%	-$83	﹤0.01%	2690
2023 Q4	$0	Sell	64 -7	-10%	-$14	﹤0.01%	2670
2023 Q3	$0	Buy	+71	New	+$135	﹤0.01%	2662

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Covestor's SMMT Position: Q2 2026 in Review

Covestor increased its Summit Therapeutics (SMMT) stake by 15% in Q2 2026, buying an estimated $975 and bringing the position to 415 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

Covestor first reported a position in SMMT in Q3 2023 and has held it in 12 quarters since. The position peaked at $27K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Covestor held 415 shares of Summit Therapeutics worth $6K as of Q2 2026.
Covestor bought 55 Summit Therapeutics shares in Q2 2026, an estimated $975.
Summit Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #1848 holding.
Covestor first reported a position in Summit Therapeutics in Q3 2023 and has held it in 12 quarters since.
Covestor's Summit Therapeutics position peaked at $27K in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.